Trinity Biotech
TRIB
40 hedge funds and large institutions have $30.2M invested in Trinity Biotech in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 6 closing their positions.
0.01% less ownership
Funds ownership: 0.1% → 0.09% (-0.01%)
11% less funds holding
Funds holding: 45 → 40 (-5)
47% less capital invested
Capital invested by funds: $57.2M → $30.2M (-$27M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$2.37M |
| 2 |
FM
Fondren Management
Houston,
Texas
|
+$592K |
| 3 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$465K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$285K |
| 5 |
BlackRock
New York
|
+$189K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
-$4.02M |
| 2 |
LAM
Lapides Asset Management
Greenwich,
Connecticut
|
-$1.64M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$1.55M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
-$394K |
| 5 |
PIM
Paradice Investment Management
Denver,
Colorado
|
-$171K |
TRIB Hedge Fund Activity: Q4 2018 in Review
40 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2018, worth a combined $30.2M — down 47% from $57.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TRIB and 1 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Stonehill Capital Management, adding an estimated $2.37M. The largest seller was Senvest Management, exiting entirely with an estimated $4.02M sold.
- 40 institutional investors held Trinity Biotech (TRIB) as of Q4 2018, down from 45 in Q3 2018.
- Funds reported $30.2M of Trinity Biotech stock for Q4 2018, down 47% quarter-over-quarter.
- 1 fund opened new Trinity Biotech positions in Q4 2018 and 6 closed out, a net change of -5 holders.
- The largest Trinity Biotech buyer in Q4 2018 was Stonehill Capital Management, an estimated $2.37M added.
- The largest Trinity Biotech seller in Q4 2018 was Senvest Management, an estimated $4.02M sold.
Based on aggregated 13F filings for Q4 2018.